研报掘金丨国海证券：维持梅花生物“买入”评级，新项目逐步落地，出海战略加速推进

Core Viewpoint - Meihua Biological's net profit attributable to shareholders is expected to increase by 20% year-on-year in the first half of 2025, driven by improved product sales and reduced costs, alongside the completion of overseas acquisition transactions [1] Group 1: Financial Performance - The net profit for the first half of 2025 is projected to grow by 20% year-on-year [1] - The profit growth is primarily attributed to cost reductions and increased sales of key products, including monosodium glutamate and 98% lysine [1] Group 2: Strategic Developments - The company has successfully completed overseas acquisition transactions, which may contribute to its growth strategy [1]